Results 1 to 10 of about 15,205 (209)

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System [PDF]

Biomedicines, 2022
This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of spontaneous hypertension (spontaneously hypertensive rats, SHRs) and whether
Fedor Simko, Tomas Baka, Peter Stanko, Kristina Repova, Kristina Krajcirovicova, Silvia Aziriova, Oliver Domenig, Stefan Zorad, Michaela Adamcova, Ludovit Paulis   +9 more
doaj   +2 more sources

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation [PDF]

Frontiers in Cardiovascular Medicine, 2022
BackgroundExisting studies have shown that sacubitril-valsartan ameliorated atrial remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with AF and heart failure.
Qingsong Chen, Yunlin Chen, Fang Qin, Huaan Du, Chunxia Gan, Bei Zhou, Na Wang, Mingyang Xiao, Zhenhong Ou, Wei Zhao, Ben Cui, Zengzhang Liu, Yuehui Yin   +12 more
doaj   +2 more sources

Efficacy and safety of sacubitril/valsartan in end-stage renal disease patients with heart failure: a review [PDF]

Annals of Medicine
Purpose End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and ...
Peiyun Li, Yupei Li, Ling Zhang
doaj   +2 more sources

Efficacy and safety of sacubitril/valsartan combined with dapagliflozin in non-diabetic patients with advanced chronic kidney disease [PDF]

Frontiers in Endocrinology
BackgroundData on the effects of sacubitril/valsartan combined with dapagliflozin in non-diabetic patients with advanced chronic kidney disease (CKD) are limited.
Huifang Wang, Xianyi Li, Chunhui Jiang, Xuemei Liu   +3 more
doaj   +2 more sources

Prescription Patterns of Sacubitril/Valsartan in an Outpatient Population Diagnosed with Heart Failure with Reduced Ejection Fraction After a Recent Hospitalization [PDF]

Epidemiologia
Background: Sacubitril/Valsartan is a first-line treatment for heart failure with reduced ejection fraction (HFrEF) according to international guidelines.
Dimitri Roustan, Hugo Bothorel, Omar Kherad   +2 more
doaj   +2 more sources

Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial [PDF]

Nature Communications
Diffuse interstitial fibrosis is associated with adverse outcomes in hypertensive heart disease and may be reversible. Sacubitril/valsartan could offer greater anti-fibrotic effects than valsartan alone.
Vivian Lee, Mayank Dalakoti, Qishi Zheng, Desiree-Faye Toh, Redha Boubertakh, Jennifer A. Bryant, Tar-Choon Aw, Chi-Hang Lee, A. Mark Richards, Javed Butler, Javier Díez, Roger Foo, Stuart A. Cook, Carolyn SP Lam, Thu-Thao Le, Calvin WL Chin   +15 more
doaj   +2 more sources

Efficacy and safety of sacubitril-valsartan in Maintenance Hemodialysis patients with hypertension:A retrospective study. [PDF]

PLoS One
Jiang L, Ran J, Zhu Y, Pan L, Yang B, Ran X, Ran Y, Ding H, Yang J, Wu S.   +9 more
europepmc   +3 more sources

Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease. [PDF]

J Clin Hypertens (Greenwich)
Murakoshi M, Kobayashi T, Kihara M, Ueda S, Suzuki Y, Gohda T.   +5 more
europepmc   +3 more sources

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction

Frontiers in Cardiovascular Medicine, 2021
Objectives: Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy.
Christof Burgdorf, Janine Brockmöller, Henrieke Strampe, Monika Januszewski, Bjoern Andrew Remppis   +4 more
doaj   +1 more source

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis

Frontiers in Pharmacology, 2023
Background: The episode of acute decompensated heart failure (ADHF) is the main cause of hospitalization for heart failure (HF). Sacubitril–valsartan has been proven to be effective in reducing the risks of hospitalization for HF in ADHF.
Tianyang Hu, Yiting Liu, Yake Lou
doaj   +1 more source